Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Inger O. Ottestad"'
Autor:
Michael S. Yule, Joshua Thompson, Khachonphat Leesahatsawat, Mariana S. Sousa, Stefan D. Anker, Jann Arends, Trude R. Balstad, Leo R. Brown, Asta Bye, Olav Dajani, Marie Fallon, Marianne J. Hjermstad, Gunnhild Jakobsen, James McDonald, Josh McGovern, Eric J. Roeland, Judith Sayers, Richard J.E. Skipworth, Inger O. Ottestad, Iain Philips, Melanie R. Simpson, Tora S. Solheim, Ola Magne Vagnildhaug, Donald McMillan, Barry J.A. Laird, Ross D. Dolan, the Cancer Cachexia Endpoints Working Group
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 3, Pp 853-867 (2024)
Abstract Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement of biomarkers featu
Externí odkaz:
https://doaj.org/article/b91388b921c54b20be4595865bc85c5f
Autor:
Leo R. Brown, Mariana S. Sousa, Michael S. Yule, Vickie E. Baracos, Donald C. McMillan, Jann Arends, Trude R. Balstad, Asta Bye, Olav Dajani, Ross D. Dolan, Marie T. Fallon, Christine Greil, Marianne J. Hjermstad, Gunnhild Jakobsen, Matthew Maddocks, James McDonald, Inger O. Ottestad, Iain Phillips, Judith Sayers, Melanie R. Simpson, Ola M. Vagnildhaug, Tora S. Solheim, Barry J.A. Laird, Richard J.E. Skipworth, the Cancer Cachexia Endpoints Working Group
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 15, Iss 3, Pp 816-852 (2024)
Abstract Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most commonly selected
Externí odkaz:
https://doaj.org/article/97fbbcfba63e4845963cae99e9a6f886
Autor:
James McDonald, Judith Sayers, Stefan D. Anker, Jann Arends, Trude Rakel Balstad, Vickie Baracos, Leo Brown, Asta Bye, Olav Dajani, Ross Dolan, Marie T. Fallon, Eilidh Fraser, Christine Griel, Aleksandra Grzyb, Marianne Hjermstad, Mariam Jamal‐Hanjani, Gunnhild Jakobsen, Stein Kaasa, Donald McMillan, Matthew Maddocks, Iain Philips, Inger O. Ottestad, Kieran F. Reid, Mariana S. Sousa, Melanie R. Simpson, Ola Magne Vagnildhaug, Richard J. E. Skipworth, Tora S. Solheim, Barry J. A. Laird, the Cancer Cachexia Endpoints Working Group
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 14, Iss 5, Pp 1932-1948 (2023)
Abstract In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures. However, it is not clear
Externí odkaz:
https://doaj.org/article/631dce5bbeae444e8aa791e121b8775f
Publikováno v:
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 137(20)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f3bba60835b3eba4a0490e4e21f71e1c
https://pubmed.ncbi.nlm.nih.gov/29094560
https://pubmed.ncbi.nlm.nih.gov/29094560